MedTrace Logo

Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma

NCT05101655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-11-15

No results posted yet for this study

Summary

Use exosome microfluidic chips to establish a combination of exosome subgroup level (exosome barcode) markers for the early diagnosis of osteosarcoma lung recurrence, and establish the basis of microfluidic chip based exosome biomarker for monitoring the early therapeutic response of the second-line therapy for recurrent osteosarcoma.

Conditions

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101655 on ClinicalTrials.gov